• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishDashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI employees
    Legal
    Terms of usePrivacy policyCookie policy

    Arrowhead Pharmaceuticals Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits

    5/12/25 4:10:03 PM ET
    $ARWR
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $ARWR alert in real time by email
    arwr-20250512
    0000879407FALSE00008794072024-11-262024-11-26

    UNITED STATES
    SECURITIES AND EXCHANGE COMMISSION
    WASHINGTON, D.C. 20549
    FORM 8-K
    CURRENT REPORT
    PURSUANT TO SECTION 13 OR 15(D) OF
    THE SECURITIES EXCHANGE ACT OF 1934
    May 12, 2025
    Date of Report
    (Date of earliest event reported)
    Arrowhead Pharmaceuticals, Inc.
    (Exact name of registrant as specified in its charter)
    Delaware001-3804246-0408024
    (State or other jurisdiction
    of incorporation)
    (Commission
    File Number)
    (IRS Employer
    Identification No.)
    177 E. Colorado Blvd, Suite 700, Pasadena, CA 91105
    (Address of principal executive offices, including Zip Code)
    (626) 304-3400
    (Registrant’s telephone number, including area code)
    Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
    ☐Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
    ☐Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
    ☐Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
    ☐Pre-commencement communications pursuant to Rule 13e-4 (c) under the Exchange Act (17 CFR 240.13e-4(c))
    Securities registered pursuant to Section 12(b) of the Act:
    Title of each class Trading Symbol(s) Name of each exchange on which registered
    Common Stock, par value $0.001 per share ARWR The Nasdaq Global Select Market
    Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
    Emerging growth company ☐
    If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐



    Item 2.02 Results of Operations and Financial Condition
    On May 12, 2025, Arrowhead Pharmaceuticals, Inc. announced and commented on its fiscal 2025 financial results for the period ended March 31, 2025. A copy of the press release is furnished herewith as Exhibit 99.1.
    In accordance with General Instruction B.2 of Form 8-K, the information in this Current Report on Form 8-K, including Exhibit 99.1, shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, whether made before or after the date hereof, except as expressly set forth by specific reference in such filing to this Current Report on Form 8-K.


    Item 9.01. Financial Statements and Exhibits.
    (d) Exhibits
    Exhibit No.Description
     
    99.1
    Press Release, dated May 12, 2025.
    104Cover Page Interactive Data File (the cover page tags are embedded within the Inline XBRL document).



    SIGNATURES
    Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.
    Date: May 12, 2025
    ARROWHEAD PHARMACEUTICALS, INC.
      
    By:/s/ Kenneth Myszkowski
     Kenneth Myszkowski
     Chief Financial Officer

    Get the next $ARWR alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $ARWR

    DatePrice TargetRatingAnalyst
    6/5/2024$31.00Neutral
    Goldman
    12/4/2023$29.00Buy
    BofA Securities
    9/19/2023$33.00Neutral
    Citigroup
    7/21/2023Outperform
    TD Cowen
    5/12/2023$40.00Outperform → Market Perform
    SVB Securities
    4/26/2023$80.00Outperform
    SMBC Nikko
    4/12/2023$21.00 → $35.00Market Perform → Outperform
    SVB Securities
    3/21/2023$27.00Mkt Perform
    Bernstein
    More analyst ratings